Literature DB >> 33970091

What Is Genitourinary Syndrome of Menopause and Why Should We Care?

Kelly Jo Peters1.   

Abstract

None: Genitourinary syndrome of menopause (GSM; previously known as vulvovaginal atrophy or atrophic vaginitis) involves symptoms of vaginal dryness, burning, and itching as well as dyspareunia, dysuria, urinary urgency, and recurrent urinary tract infections. It is estimated that nearly 60% of women in menopause experience GSM but the majority of these women do not bring up this concern with their health care provider. Studies also show that only 7% of health care providers ask women about this condition. This may be due to embarrassment or thinking this is a normal part of aging, both by patients and health care providers. This condition is progressive and may affect many aspects of a woman's physical, emotional, and sexual health. This article is intended to address the signs, symptoms, and significant impact this condition can have for women and help health care providers be more comfortable knowing how to ask about GSM, diagnosis it, and review the various treatment options that are available.
Copyright © 2021 The Permanente Press. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33970091      PMCID: PMC8817901          DOI: 10.7812/TPP/20.248

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  13 in total

1.  A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women.

Authors:  Cheng-Yu Long; Cheng-Min Liu; Shih-Cheng Hsu; Chin-Hu Wu; Chiu-Lin Wang; Eing-Mei Tsai
Journal:  Menopause       Date:  2006 Sep-Oct       Impact factor: 2.953

Review 2.  Oestrogens for preventing recurrent urinary tract infection in postmenopausal women.

Authors:  C Perrotta; M Aznar; R Mejia; X Albert; C W Ng
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

3.  ACOG Committee Opinion No. 659: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer.

Authors:  Ruth Farrell
Journal:  Obstet Gynecol       Date:  2016-03       Impact factor: 7.661

4.  Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study.

Authors:  D Grady; J S Brown; E Vittinghoff; W Applegate; E Varner; T Snyder
Journal:  Obstet Gynecol       Date:  2001-01       Impact factor: 7.661

5.  Workshop on normal reference ranges for estradiol in postmenopausal women: commentary from The North American Menopause Society on low-dose vaginal estrogen therapy labeling.

Authors:  JoAnn V Pinkerton; James H Liu; Nanette F Santoro; Rebecca C Thurston; Hadine Joffe; Stephanie S Faubion; JoAnn E Manson
Journal:  Menopause       Date:  2020-06       Impact factor: 2.953

6.  Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women.

Authors:  Salvatore Dessole; Giovanni Rubattu; Guido Ambrosini; Omar Gallo; Giampiero Capobianco; Pier Luigi Cherchi; Roberto Marci; Erich Cosmi
Journal:  Menopause       Date:  2004 Jan-Feb       Impact factor: 2.953

Review 7.  The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis.

Authors:  R T Pavlović; S M Janković; J R Milovanović; S M Stefanović; M M Folić; O Z Milovanović; C Mamillapalli; M N Milosavljević
Journal:  Clin Breast Cancer       Date:  2019-08-21       Impact factor: 3.225

Review 8.  Local oestrogen for vaginal atrophy in postmenopausal women.

Authors:  Anne Lethaby; Reuben Olugbenga Ayeleke; Helen Roberts
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31

9.  The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.

Authors: 
Journal:  Menopause       Date:  2020-09       Impact factor: 3.310

Review 10.  Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.

Authors:  Lin H Soe; Gregory T Wurz; Chiao-Jung Kao; Michael W Degregorio
Journal:  Int J Womens Health       Date:  2013-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.